Dr. Kenneth Cheng to Speak At South Carolina Society of Nuclear Medicine Conference
(Business Wire)...~~~ Dr. Cheng will discuss his clinical experience with Cotara(TM), Peregrine`s Tumor Necrosis Therapy (TNT) drug.......Dr. Cheng participated as a researcher in the Phase I and II brain cancer trials for Cotara that were conducted at the Medical University of South Carolina.......Cotara is a radiolabeled monoclonal antibody that targets the necrotic core of tumors....- Mar 02 7:51 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/bw/010302/2057.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines